Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing CoFRA:17Q1 -1.53%90 PE Ratio without NRI is 21.86 as of Jul. 26, 2026, which is 60% below its 10-year median of 54.91. GuruFocus rates FRA:17Q1 with a GF Score™ of 90/100 and a GF Value™ of €2.23. The stock has 9 warning signs investors should review. Among 265 Biotechnology companies, Pharmaron Beijing Co ranks worse than 69.81% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-26), Pharmaron Beijing Co's share price is €2.58.
Pharmaron Beijing Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €0.12. Therefore, Pharmaron Beijing Co's PE Ratio without NRI for today is 21.86.
During the past 12 years, Pharmaron Beijing Co's highest PE Ratio without NRI was 145.96. The lowest was 16.57. And the median was 54.91.
Pharmaron Beijing Co's EPS (Basic) for the
three
months ended in Mar. 2026 was €0.02.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.12.
Pharmaron Beijing Co (FRA:17Q1) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Pharmaron Beijing Co PE Ratio without NRI Related Terms
Pharmaron Beijing Co PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:17Q1 vs VRTX, REGN, ALNY: PE Ratio without NRI Comparison
For the Biotechnology subindustry, Pharmaron Beijing Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's PE Ratio without NRI falls into.
Pharmaron Beijing Co PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Pharmaron Beijing Co's Share Price of today is €2.58.
Pharmaron Beijing Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Pharmaron Beijing Co (FRA:17Q1) has a PE Ratio without NRI of 21.86 as of Jul. 26, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Pharmaron Beijing Co and its competitors. This is 60% below median its historical median of 54.91. Over the past decade, Pharmaron Beijing Co's PE Ratio without NRI has ranged from 16.57 to 145.96. According to the industry distribution chart, Pharmaron Beijing Co ranks #185 out of 265 companies in the Biotechnology industry, placing it in the top 69.8%.
Is Pharmaron Beijing Co's PE Ratio without NRI too high?
Pharmaron Beijing Co's current PE Ratio without NRI of 21.86 is 60% below median its 10-year median of 54.91. Over the past 10 years, this metric has ranged from a low of 16.57 to a high of 145.96. The Biotechnology industry median PE Ratio without NRI is 24.55. Pharmaron Beijing Co's value of 21.86 is 11% below this industry median. Based on the distribution chart, Pharmaron Beijing Co ranks #185 out of 265 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharmaron Beijing Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's PE Ratio without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #185 out of 265 companies for PE Ratio without NRI. This places Pharmaron Beijing Co in the lower half of its industry. The industry median PE Ratio without NRI is 24.55. Pharmaron Beijing Co's value of 21.86 is 11% below this benchmark. Historically, Pharmaron Beijing Co's own PE Ratio without NRI has ranged from 16.57 to 145.96 over the past decade. While the company's 10-year median is 54.91 vs. the industry median of 24.55, Pharmaron Beijing Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 24.55, based on 265 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaron Beijing Co's current PE Ratio without NRI of 21.86 is 11% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Pharmaron Beijing Co and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 24.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaron Beijing Co's current PE Ratio without NRI is 21.86, which is 60% below median its own 10-year median of 54.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (FRA:17Q1) has a current PE Ratio without NRI of 21.86. The stock's GF Value™ is €2.23, compared to a current price of €2.58 — trading 15.7% above its estimated fair value. The current PE Ratio without NRI is 21.86, which is 60% below median its 10-year median of 54.91 and 11% below the Biotechnology industry median of 24.55. Pharmaron Beijing Co's overall GF Score™ is 90/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Pharmaron Beijing Co (FRA:17Q1), the current PE Ratio without NRI is 21.86 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (FRA:17Q1) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of €2.58 is trading 15.7% above its estimated GF Value™ of €2.23.
Key valuation signals for FRA:17Q1:
PE Ratio without NRI: 21.86 (60% below median its 10-year median of 54.91)
GF Value™: €2.23 vs. price of €2.58 (15.7% above fair value)
Industry Position: 11% below the Biotechnology median (#185 of 265)
No single metric tells the full story. See the FRA:17Q1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
90GF Score
Get the complete analysis for FRA:17Q1
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:17Q1 has been successfully added to your 
